B7/CD28 interaction inhibitor 1 5 mg | 98.89%
TargetMol
B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor.
More Information Supplier PageB7/CD28 interaction inhibitor 1
Search Results
PF-4136309 10 mg | 99.52%
TargetMol
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
More Information Supplier PagePF-4136309
PF-4136309 50 mg | 99.52%
TargetMol
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
More Information Supplier PagePF-4136309
PF-4136309 5 mg | 99.52%
TargetMol
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
More Information Supplier PagePF-4136309
Fasudil hydrochloride 500 mg | Purity Not Available
TargetMol
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
More Information Supplier PageFasudil hydrochloride
Fasudil hydrochloride 200 mg | Purity Not Available
TargetMol
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
More Information Supplier PageFasudil hydrochloride
Fasudil hydrochloride 100 mg | Purity Not Available
TargetMol
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
More Information Supplier PageFasudil hydrochloride
UNC1999 5 mg | 99.49%
TargetMol
UNC1999 is a orally bioavailable, effective and specific inhibitor of EZH2 (IC50=2 nM) and EZH1 (IC50=45).
More Information Supplier PageUNC1999
UNC1999 50 mg | 99.49%
TargetMol
UNC1999 is a orally bioavailable, effective and specific inhibitor of EZH2 (IC50=2 nM) and EZH1 (IC50=45).
More Information Supplier PageUNC1999
UNC1999 2 mg | 99.49%
TargetMol
UNC1999 is a orally bioavailable, effective and specific inhibitor of EZH2 (IC50=2 nM) and EZH1 (IC50=45).
More Information Supplier PageUNC1999